Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KZIA | US
-0.57
-7.09%
Healthcare
Biotechnology
31/12/2023
17/03/2026
7.53
8.30
8.51
7.57
Kazia Therapeutics Limited an oncology-focused biotechnology company develops anti-cancer drugs. Its lead development candidate is Paxalisib a small molecule brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which is developed as a potential therapy for glioblastoma. It is also developing EVT801 an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney Australia.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
115.6%1 month
129.7%3 months
131.9%6 months
153.4%-
-
4.76
0.07
0.01
-0.71
0.94
-
-17.52M
250.64M
250.64M
-
-100.00M
-
35.60
-186.37
0.20
1.00
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.49
Range1M
5.58
Range3M
7.34
Rel. volume
0.29
Price X volume
413.56K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc | VRCA | Biotechnology | 6.31 | 269.24M | 2.27% | n/a | -348.20% |
| Northwest Biotherapeutics Inc | NWBO | Biotechnology | 0.2 | 250.65M | -6.54% | n/a | 0.00% |
| BioLineRx Ltd | BLRX | Biotechnology | 2.71 | 237.75M | 3.04% | n/a | 223.55% |
| CEL-SCI Corporation | CVM | Biotechnology | 3.6 | 229.63M | 1.98% | n/a | 143.19% |
| Verastem Inc | VSTM | Biotechnology | 5.67 | 228.18M | -2.41% | n/a | 104.63% |
| LogicBio Therapeutics Inc | LOGC | Biotechnology | 8.4804 | 222.82M | 0.36% | n/a | 0.00% |
| Fennec Pharmaceuticals Inc | FENC | Biotechnology | 7.76 | 218.66M | -0.51% | 64.86 | -2193.44% |
| Alector Inc | ALEC | Biotechnology | 2.23 | 217.03M | 0.90% | n/a | 23.98% |
| OABI | OABI | Biotechnology | 1.83 | 216.24M | 0.00% | n/a | 8.27% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 14.51 | 214.70M | 1.04% | n/a | 13.35% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Marine Products Corporation | MPX | Recreational Vehicles | 7.14 | 247.88M | 0.14% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 14.45 | 161.23M | -2.82% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 8.6 | 138.09M | -0.06% | n/a | 286.96% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.26 | 101.97M | -0.16% | 9.09 | 39.79% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.9 | 100.23M | 0.58% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.16 | 69.88M | -1.24% | 14.48 | 7.10% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.85 | 27.03M | -3.14% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.5906 | 11.41M | -0.91% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.68 | 5.60M | -1.87% | n/a | 204.46% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3268 | 3.11M | -8.66% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.71 | 0.53 | Cheaper |
| Ent. to Revenue | 0.94 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.76 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 131.95 | 72.80 | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 250.64M | 3.66B | Emerging |